HSP70 as a Target for Correction of Wilson Disease Causing ATP7B Mutants Article Swipe

MAKE IMPACT

Mafalda Concilli · YOU? · · 2017 · Open Access · · DOI: https://doi.org/10.21954/ou.ro.0000c67d

Copper (Cu) is an essential micronutrient, which operates as a cofactor of enzymes regulating a wide range of critical physiological processes. However, Cu overload compromises the redox balance in cells and tissues causing serious toxicity. Removal of excess Cu from the body is driven be Cu-transporting ATPase ATP7B, which sequesters the potentially toxic metal and mediates its excretion into the bile. Mutations in the ATP7B result in Wilson disease (WD) that is caused by the toxic accumulation of Cu in the liver due to the loss of ATP7B function. The most frequent ATP7B mutant, H1069Q, still preserves a significant Cu-transporting activity, but undergoes retention and degradation in the endoplasmic reticulum (ER). Thus, rescue of ATP7B-H1069Q from the ER is expected to recover mutant function and, hence, would be beneficial for a large group of WD patients. Unfortunately, specific targets as well as safe drugs for correction of ATP7B-H1069Q mutant remain to be uncovered. Comparing interactomes of WT and H1069Q variants of ATP7B, I found HSP70 as a specific mutant interactor that regulates ER retention and degradation of ATP7B-H1069Q. HSP70 suppression (with either RNAi or allosteric inhibitor) improved stability of the mutant and facilitated its export from the ER to the Golgi and post-Golgi copper excretion sites. These findings prompted me to look for a safe way to inhibit HSP70 and rescue the ATP7B mutant. To this end several bioinformatics tools were employed to search for FDA-approved drugs that modulate HSP70 expression or exhibit structural similarity to HSP70 inhibitors. As a result, Domperidone and glucocorticoid receptor agonists were identified and validated as effective correctors of ATP7B mutant. In summary, my findings suggest a key role for HSP70 in proteostasis of ATP7B-H1069Q and revealed FDA-approved compounds as safe drugs for ATP7B mutant correction and, thus, for the normalization of Cu homeostasis in Wilson disease patients.

Type

dissertation

Language

en

Landing Page

https://doi.org/10.21954/ou.ro.0000c67d

OA Status

green

Related Works

20

OpenAlex ID

https://openalex.org/W2765358332

Raw OpenAlex JSON

OpenAlex ID

https://openalex.org/W2765358332

Canonical identifier for this work in OpenAlex

DOI

https://doi.org/10.21954/ou.ro.0000c67d

Digital Object Identifier

Title

HSP70 as a Target for Correction of Wilson Disease Causing ATP7B Mutants

Work title

Type

dissertation

OpenAlex work type

Language

en

Primary language

Publication year

2017

Year of publication

Publication date

2017-01-01

Full publication date if available

Authors

Mafalda Concilli

List of authors in order

Landing page

https://doi.org/10.21954/ou.ro.0000c67d

Publisher landing page

Open access

Yes

Whether a free full text is available

OA status

green

Open access status per OpenAlex

OA URL

https://doi.org/10.21954/ou.ro.0000c67d

Direct OA link when available

Concepts

Mutant, Endoplasmic reticulum, Golgi apparatus, Cell biology, Endoplasmic-reticulum-associated protein degradation, Biology, Hsp70, Allosteric regulation, Biochemistry, Chemistry, Unfolded protein response, Enzyme, Heat shock protein, Gene

Top concepts (fields/topics) attached by OpenAlex

Cited by

0

Total citation count in OpenAlex

Related works (count)

20

Other works algorithmically related by OpenAlex

Full payload